Children's Hospital Colorado

Running trials

• Not yet recruiting

  COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE"

  NCT07281027· Phase 3· Yale University· Source

• Recruiting

  Headache Education and Awareness vs. Daily Mindfulness Strategies - Understanding Pain

  NCT07513662· University of Colorado, Denver· Source

• Not yet recruiting

  IMPACT-Ready Study

  NCT07931690· Coalition for Aligning Science· Source

• Recruiting

  Improving Sleep Health and Circadian Timing to Support Cardiometabolic Health in Adolescents

  NCT07618117· University of Colorado, Denver· Source

• Recruiting

  Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)

  NCT07817875· Phase 3· Eli Lilly and Company· Source

• Not yet recruiting

  Rethinking Early Airway Clearence Therapies

  NCT07696338· Nicole Hamblett· Source

• Recruiting

  BOND: Direct Breastfeeding to Enhance Maternal and Infant Health in Congenital Heart Disease

  NCT07582848· Carelon Research· Source

• Recruiting

  Prenatally-initiated Psychological Intervention for Mothers of Infants With Congenital Heart Disease (CHD)

  NCT07582861· Carelon Research· Source

• Recruiting

  A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)

  NCT07466316· Phase 3· Children's Oncology Group· Source

• Recruiting

  Prospective Natural History Study of POLG Disease

  NCT07775872· The POLG Foundation· Source

• Recruiting

  A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

  NCT07012044· Phase 1· National Cancer Institute (NCI)· Source

• Recruiting

  Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease

  NCT07252050· Phase 1/2· Arkansas Children's Hospital Research Institute· Source

• Recruiting

  A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction

  NCT07192952· Phase 3· Bayer· Source

• Recruiting

  First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.

  NCT07586618· Phase 1· Allterum Therapeutics, Inc· Source

• Recruiting

  Modulation of the Immune System in Down Syndrome for Improved Outcomes and Neurodevelopment - 1

  NCT07598643· Phase 2· University of Colorado, Denver· Source

• Recruiting

  A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)

  NCT05199688· Phase 3· Hoffmann-La Roche· Source

• Not yet recruiting

  Occlutech AFR Fontan Study

  NCT07532369· Occlutech International AB· Source

• Recruiting

  A Pragmatic Clinical Trial of the WE BEAT Well-Being Education Program in Adolescent Congenital Heart Disease: WE BEAT CHD Study

  NCT07525843· Carelon Research· Source

• Recruiting

  A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis

  NCT07158242· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Starlight Cardiovascular Lifeline Ductus Arteriosus Stent IDE Study

  NCT07114718· Starlight Cardiovascular Inc· Source

• Recruiting

  A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction

  NCT07188805· Phase 3· Bayer· Source

• Recruiting

  A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma

  NCT07085338· Phase 2· St. Jude Children's Research Hospital· Source

• Enrolling by invitation

  A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)

  NCT07156578· Phase 2· Rhythm Pharmaceuticals, Inc.· Source

• Recruiting

  A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)

  NCT06760546· Phase 3· Rhythm Pharmaceuticals, Inc.· Source

• Recruiting

  A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy

  NCT07047144· Phase 2· Scholar Rock, Inc.· Source

• Recruiting

  A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.

  NCT07029828· Phase 3· Pfizer· Source

• Recruiting

  Type 1 Diabetes REst for Metabolic Health

  NCT06627504· University of Colorado, Denver· Source

• Recruiting

  Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

  NCT06333899· Early phase 1· Nationwide Children's Hospital· Source

• Active, not recruiting

  A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata

  NCT07029711· Phase 3· Pfizer· Source

• Recruiting

  Safety of Short-course of NSAIDs in Pediatric Patients With CKD

  NCT06860711· Phase 4· University of Colorado, Denver· Source

• Recruiting

  ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas

  NCT06838676· Phase 2· Nationwide Children's Hospital· Source

• Recruiting

  Simulation Trial of Telemedical Support for Paramedics

  NCT06441760· Boston Medical Center· Source

• Active, not recruiting

  Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma

  NCT06894979· Phase 1· Children's Oncology Group· Source

• Recruiting

  Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  NCT06317662· Phase 2· National Cancer Institute (NCI)· Source

• Active, not recruiting

  A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome

  NCT06872125· Phase 3· Stoke Therapeutics, Inc· Source

• Recruiting

  TIDES 2.0: Prevalence and Longitudinal Course of Depression, Anxiety, and Behavior Problems in Children With Cystic Fibrosis Under 12 Years of Age

  NCT07048574· State University of New York at Buffalo· Source

• Recruiting

  A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  NCT06124157· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL)

  NCT06683092· Boston Children's Hospital· Source

• Recruiting

  A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

  NCT06401330· Phase 3· Children's Oncology Group· Source

• Recruiting

  Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma

  NCT06647953· Phase 3· Children's Oncology Group· Source

• Recruiting

  Navigating Together for Equitable Asthma Management for Children in Families Who Communicate in Language Other Than English

  NCT06239844· University of Colorado, Denver· Source

• Recruiting

  Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia

  NCT06376162· Phase 1· PedAL BCU, LLC· Source

• Enrolling by invitation

  Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0

  NCT06823115· Indiana University· Source

• Recruiting

  Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

  NCT06513962· Phase 3· Children's Oncology Group· Source

• Enrolling by invitation

  A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)

  NCT06908226· Phase 3· Longboard Pharmaceuticals· Source

• Recruiting

  A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1

  NCT06541847· Phase 2· Healx Limited· Source

• Recruiting

  Optimal Pediatric Heart Transplant Immunosuppression With MicroRNAs

  NCT06532890· Northwestern University· Source

• Recruiting

  A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

  NCT06247787· Phase 1· Children's Oncology Group· Source

• Recruiting

  Study of Olutasidenib and Temozolomide in HGG

  NCT06161974· Phase 2· Rigel Pharmaceuticals· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo

  NCT06548360· Phase 3· Incyte Corporation· Source

Showing 50 of 284.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers66 recruiting
• Acute lymphoblastic leukaemia15 recruiting
• Acute myeloid leukaemia10 recruiting
• Cystic fibrosis9 recruiting
• Sarcoma9 recruiting
• Epilepsy7 recruiting
• Migraine7 recruiting
• Neuroblastoma7 recruiting
• Obesity7 recruiting
• Congenital heart disease6 recruiting
• Glioblastoma5 recruiting
• Kidney cancer5 recruiting
• Chronic kidney disease4 recruiting
• Down syndrome4 recruiting
• Heart failure4 recruiting
• High blood pressure4 recruiting
• Hodgkin lymphoma4 recruiting
• Type 2 diabetes4 recruiting
• Asthma3 recruiting
• Chronic lymphocytic leukaemia3 recruiting
• Myelodysplastic syndromes3 recruiting
• Ovarian cancer3 recruiting
• Pulmonary arterial hypertension3 recruiting
• Chronic myeloid leukaemia2 recruiting
• Duchenne muscular dystrophy2 recruiting
• Hearing loss2 recruiting
• Lupus (SLE)2 recruiting
• Myeloproliferative neoplasms2 recruiting
• Sickle cell disease2 recruiting
• Spinal muscular atrophy2 recruiting
• Alopecia areata1 recruiting
• Aplastic anaemia1 recruiting
• Autism1 recruiting
• Coeliac disease1 recruiting
• Colorectal cancer1 recruiting
• Crohn's disease1 recruiting
• Cytomegalovirus infection1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Endometrial cancer1 recruiting
• Follicular lymphoma1 recruiting
• Hydrocephalus1 recruiting
• Liver and biliary tract cancer1 recruiting
• Lung cancer1 recruiting
• Melanoma1 recruiting
• Multiple myeloma1 recruiting
• Myasthenia gravis1 recruiting
• Neuroendocrine tumours1 recruiting
• Neuromyelitis optica (NMOSD)1 recruiting
• Obstructive sleep apnoea1 recruiting
• Pancreatic cancer1 recruiting
• Psoriasis1 recruiting
• Psoriatic arthritis1 recruiting
• Retinitis pigmentosa1 recruiting
• Rheumatoid arthritis1 recruiting
• Spinal cord injury1 recruiting
• Stroke1 recruiting
• Thalassaemia1 recruiting
• Type 1 diabetes1 recruiting
• Ulcerative colitis1 recruiting
• Vitiligo1 recruiting

Closed trials

• Terminated

  An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM)

  NCT06961344· Phase 2· Tisento Therapeutics· Source

• Completed

  A Phase 2b Study of Zagociguat in Patients With MELAS

  NCT06402123· Phase 2· Tisento Therapeutics· Source

• Completed

  A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity

  NCT06046443· Phase 2· Rhythm Pharmaceuticals, Inc.· Source

• Completed

  Mindfulness-Based Intervention for Adolescents With Chronic Migraine

  NCT06414109· University of Colorado, Denver· Source

• Terminated

  Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants

  NCT06566092· Phase 1· Iovance Biotherapeutics, Inc.· Source

• Completed

  Therapies for Down Syndrome Regression Disorder

  NCT05662228· Phase 2· University of Colorado, Denver· Source

• Completed

  A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complex

  NCT05864846· Phase 4· Jazz Pharmaceuticals· Source

• Recruiting

  Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

  NCT05714085· Phase 2/3· Merck Sharp & Dohme LLC· Source

• Terminated

  A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)

  NCT05600426· Phase 3· Boston Children's Hospital· Source

• Recruiting

  Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors

  NCT05278208· Phase 1/2· Nationwide Children's Hospital· Source

• Completed

  Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study

  NCT05530356· University of Colorado, Denver· Source

• Completed

  Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension

  NCT04039464· Phase 3· Johns Hopkins University· Source

• Completed

  Real-Time Assessment of Lung Structure and Function in Children and Young Adults With CF Using Electrical Impedance Tomography

  NCT05455671· University of Colorado, Denver· Source

• Completed

  Pilot Study to Evaluate a Voice Journaling Application in Adolescents With Cystic Fibrosis

  NCT05420844· University of Colorado, Denver· Source

• Terminated

  A Study Evaluating the Efficacy and Safety of IV L-Citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in Pediatric Patients Undergoing Surgery for Congenital Heart Defects

  NCT05253209· Phase 3· Asklepion Pharmaceuticals, LLC· Source

• Completed

  A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome

  NCT05153434· Phase 2· Aardvark Therapeutics, Inc.· Source

• Completed

  Mindfulness-Based Intervention for Depression and Insulin Resistance in Adolescents

  NCT04992299· Colorado State University· Source

• Completed

  EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway

  NCT05093634· Phase 3· Rhythm Pharmaceuticals, Inc.· Source

• Completed

  Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)

  NCT04965597· Phase 2· Fred Hutchinson Cancer Center· Source

• Completed

  Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam

  NCT05156320· Phase 3· Scholar Rock, Inc.· Source

• Completed

  A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both

  NCT05260021· Phase 3· Eli Lilly and Company· Source

• Completed

  Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity

  NCT04966741· Phase 3· Rhythm Pharmaceuticals, Inc.· Source

• Terminated

  A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome

  NCT05163314· Phase 3· Takeda· Source

• Completed

  A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling

  NCT04773782· Phase 1/2· Blueprint Medicines Corporation· Source

• Completed

  Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older

  NCT05153317· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Completed

  CNS Qualitative Interview

  NCT05219149· University of Colorado, Denver· Source

• Completed

  A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome

  NCT04938427· Phase 3· Takeda· Source

• Completed

  A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

  NCT05096221· Phase 3· Sarepta Therapeutics, Inc.· Source

• Completed

  A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

  NCT05076149· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Completed

  A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)

  NCT05033080· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Completed

  Allergic Disease Onset Prevention Study

  NCT05003804· Phase 1/2· Siolta Therapeutics, Inc.· Source

• Terminated

  Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma

  NCT04751383· Phase 1· National Cancer Institute (NCI)· Source

• Completed

  The PROMISE Pediatric Study 6 to 11 Years Old

  NCT04613128· Nicole Hamblett· Source

• Terminated

  A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG)

  NCT04771897· Phase 1· Bexion Pharmaceuticals, Inc.· Source

• Completed

  A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD)

  NCT04729907· Phase 3· Biogen· Source

• Terminated

  Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMD

  NCT04632940· Phase 3· Kyntra Bio· Source

• Completed

  A Study to Learn About the Effect of Nusinersen (BIIB058) Given as Injections to Children With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec (RESPOND)

  NCT04488133· Phase 4· Biogen· Source

• Completed

  Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)

  NCT04562766· Phase 3· Principia Biopharma, a Sanofi Company· Source

• Completed

  A Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension

  NCT04257929· Phase 2· Harmony Biosciences Management, Inc.· Source

• Completed

  Informational Meetings for Planning and Coordinating Treatment

  NCT04330833· Indiana University· Source

• Completed

  Technology-assisted Language Intervention (TALI)

  NCT04857255· Children's Hospital Medical Center, Cincinnati· Source

• Terminated

  A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome

  NCT04572243· Phase 3· Eisai Inc.· Source

• Completed

  A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080)

  NCT04447755· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas

  NCT04295759· Phase 1· Pediatric Brain Tumor Consortium· Source

• Completed

  An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome

  NCT04442295· Phase 1/2· Stoke Therapeutics, Inc· Source

• Terminated

  9-ING-41 in Pediatric Patients With Refractory Malignancies.

  NCT04239092· Phase 1· Actuate Therapeutics Inc.· Source

• Completed

  Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy

  NCT04089566· Phase 3· Biogen· Source

• Recruiting

  Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

  NCT04278404· Duke University· Source

• Completed

  Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA TC Combination Therapy in Participants With Cystic Fibrosis Who Are 6 Years of Age and Older

  NCT04183790· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Completed

  PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study

  NCT04129931· Phase 2· University of North Carolina, Chapel Hill· Source

Showing 50 of 116.

Conditions

Diseases this institution publishes on or runs trials for.

• Asthma57 works · 7 trials
• Epilepsy41 works · 17 trials
• Cystic fibrosis40 works · 20 trials
• Congenital heart disease29 works · 15 trials
• Childhood cancers23 works · 212 trials
• Down syndrome19 works · 10 trials
• Acute lymphoblastic leukaemia17 works · 34 trials
• Duchenne muscular dystrophy15 works · 12 trials
• Coeliac disease12 works · 1 trial
• Neuroblastoma11 works · 37 trials
• Sickle cell disease9 works · 4 trials
• Cerebral palsy8 works · 1 trial
• Dilated cardiomyopathy7 works · 0 trials
• Aplastic anaemia5 works · 3 trials